explore -WSS

explore

author：entertainment 2025-09-04 05:52:32 - browse：92857

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： European officials brace for rough respiratory virus season

knowledge

Wikipedia

WSS

Senators tussle over abortion against the backdrop of a presidential campaign

With Roe v Wade overturned, abortion providers work to adapt

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Health insurers' Q3 question: how much care are people getting?

The Karikó problem: Lessons for funding basic research

CDC picks Alphabet's Verily for wasterwater surveillance contract

explore

explore

Lobbying power of AI, software-enabled devices

knowledge

Walensky prepares to leave CDC — and Congress — behind

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Malaria cases in Florida and Texas: Here’s what you need to know

Will an HIV vaccine ever be a reality?

At least 13 dead in Texas as scorching temps continue

FTC loses bid to block Novant's North Carolina hospital merger

Moonlake's readout produced a cash windfall. Risks remain

The stability of $0 premiums in Medicare Advantage

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Congress needs to close a vaccine

explore

FTC loses bid to block Novant's North Carolina hospital merger

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

6 solutions to address cancer drug shortages and others

What we owe ALS patients — and why one company fell short

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The stability of $0 premiums in Medicare Advantage

leisure time

knowledge

Wikipedia

explore